How Did the Implementation of the EU AI Act Influence the Venture Capital Flow into High-Risk Classified Startups Compared to Those in the US and China?

Ask an AI founder in Paris, Austin, and Beijing the same question, "what does regulation mean for my fundraising?" and you get three completely different answers. In Paris, it means a compliance checklist that grows heavier every year and a due-diligence process where lawyers now sit next to term sheets. In Austin, it means moving fast, disclosing little, and letting the market decide what counts as risky. In Beijing, it means aligning your roadmap with state industrial policy long before a VC ever wires a dollar. These are not abstract philosophical differences. They show up directly in capital allocation, deal speed, and which categories of AI startup can even get funded in the first place. This piece traces exactly how the EU AI Act's high-risk regime has reshaped venture flows into regulated AI categories, and stacks that against what has actually happened in the US and China over the same period.

A Regulation That Arrived in Slow Motion

The EU AI Act entered into force in August 2024, but its real impact on capital allocation only became visible once the phased obligations began landing one by one. Bans on unacceptable-risk practices, such as real-time public biometric surveillance and social scoring, took effect in February 2025. Governance rules and obligations for general-purpose AI models followed in August 2025. The heaviest tier, obligations for high-risk systems in hiring, credit scoring, healthcare, biometrics, education, and critical infrastructure, was originally set for August 2026, but a political agreement on the so-called "AI Omnibus" in May 2026 pushed the toughest Annex III deadlines out to December 2027, with product-embedded systems like medical devices and machinery given until August 2028.

For venture investors, this staggered rollout has mattered as much as the substance of the rules themselves. Every delay and clarification resets how founders and term sheets price regulatory risk. A Series A investor underwriting a hiring-AI startup in 2024 was pricing in an August 2026 compliance cliff; by mid-2026, that same investor was re-underwriting the same company against a December 2027 cliff, an eighteen-month swing that changes runway assumptions, headcount plans for compliance staff, and exit timelines. Draft Commission guidelines on what actually counts as "high-risk," published in May 2026, only added to this: they interpret the conformity assessment test broadly enough that more AI systems embedded in regulated products may fall under the regime than most businesses had assumed, with a further consultation window running to July 2026 before anything is finalized.

The High-Risk Tax, in Actual Numbers

Being classified as high-risk under the Act is not a label, it is a cost structure. European Commission impact studies and independent analyses put annual per-system compliance spend at roughly €29,000, with third-party conformity assessments alone running €10,000 to €40,000 and initial certification for a single high-risk system exceeding €50,000 before ongoing monitoring is even counted. High-risk systems are estimated to account for 60 to 70 percent of total AI compliance spending across the EU, even though they represent a minority of deployed systems.

The gap between regulatory intent and founder expectation compounds the problem. The Commission's own impact assessment expected only 5 to 15 percent of AI applications to ultimately be classified as high-risk. But a survey of 113 EU AI startups found a third of founders believed their own systems would land in that bucket, roughly three times the official estimate. A separate study of 106 enterprise AI systems found 18 percent were clearly high-risk, 42 percent clearly low-risk, and a striking 40 percent unclear, concentrated in exactly the categories investors care most about: critical infrastructure, employment, and law enforcement. That "unclear" bucket is where a lot of European venture capital simply refuses to go, because ambiguity is harder to underwrite than a known cost.

There's also a talent-and-tooling bottleneck behind the price tag. Conformity assessments require notified bodies, and Europe has not built out nearly enough of them; the shortage of qualified assessors is already delaying market entry for smaller players who can't get in the queue, regardless of how much capital they've raised. A well-funded startup with a completed Series B can still be stuck waiting for a compliance body to have capacity, which is not a problem money alone solves.

Where the Capital Actually Went: The Aggregate Numbers

The clearest evidence sits in the aggregate figures. OECD's 2026 review of AI venture capital found the United States captured about 75 percent of global AI VC deal value in 2025, versus 6 percent for the EU27 and 5 percent for China. Crunchbase's Q1 2026 data showed the gap widening further still: US-based companies took 83 percent of all global venture funding that quarter, up from 71 percent a year earlier. Four mega-rounds alone, OpenAI's $122 billion, Anthropic's $30 billion, xAI's $20 billion, and Waymo's $16 billion, absorbed 188 billion, or roughly 63 percent of all global venture capital in a single quarter. AI captured over 80 percent of total global venture funding in that same quarter, a level of concentration that has no historical precedent.

China, by contrast, was the second-largest single-country destination in Q1 2026, pulling in just over16 billion and already exceeding its full-year 2025 total early into the year, a sign that capital there is recovering after a multi-year lull, even if it remains a fraction of US volume. By Q1 2026 alone, China's AI-specific startup funding had tripled year over year to roughly $16 billion according to Zero2IPO data, driven heavily by large language model developers and embodied AI (robotics) firms. Across all of 2026, China's total AI investment reached an estimated $125 billion, about 38 percent of global AI funding by some counts, though the great majority of that is government-directed industrial spending rather than private venture capital in the Western sense.

Europe's own numbers, via Atomico's State of European Tech 2025 report, show total venture investment holding roughly flat at 44 billion for the year, with AI and deep tech capturing a growing 36 percent share of that pool, up from 19 percent in 2021. But the same report puts Europe's AI-specific capital at around14 billion against 146 billion in the US for comparable categories, a ten-to-one gap that has not meaningfully closed. Nearly 70 percent of founders surveyed by Atomico consider Europe's regulatory environment too restrictive. Fifteen percent had already relocated their headquarters, and of those who moved or seriously considered it, the substantial majority pointed to the United States as the destination, with 57 percent of relocators and 73 percent of those who merely considered it naming the US specifically.

Company-Level Evidence: Three Case Studies

Aggregate statistics can hide as much as they reveal, so it helps to look at what's actually happening inside individual companies operating in each regime.

Mistral AI (France) — Europe's Flagship, Still a Fraction of the US Leaders

Mistral AI is the clearest test case for whether "regulatory moat" theory holds up under real capital pressure. Founded in Paris in 2023, it raised a €600 million Series B in June 2024 at a €5.8 billion valuation, then a €1.7 billion Series C in September 2025 at €11.7 billion, led by ASML, which took an 11 percent stake. In March 2026 it added830 million in debt financing to fund a new data center outside Paris. By June 2026 it was reportedly in talks to raise roughly €3 billion at a €20 billion valuation, nearly doubling its value in under a year. That is genuinely fast growth by any historical standard, and it shows European AI capital formation is not frozen. But set against its direct US counterparts, the scale gap is stark: at a prospective $20 billion or so, Mistral would still be worth roughly 2 percent of Anthropic's reported $965 billion valuation and a similarly small fraction of OpenAI's. Mistral's own revenue trajectory, crossing $400 million in annualized recurring revenue with a target of $1 billion by the end of 2026, is healthy but modest next to the scale of capital being deployed into US frontier labs in the same window.

OpenAI and Anthropic (United States) — Capital Concentration at an Unprecedented Scale

The American side of the ledger in 2026 is defined by capital concentration rather than breadth. A handful of frontier labs are absorbing sums that dwarf entire national venture ecosystems. Anthropic's valuation reportedly reached roughly 965 billion after a Series H round in the tens of billions, briefly overtaking OpenAI in private-market valuation for the first time. OpenAI itself was preparing a public listing process later in 2026 while still raising private capital at scale. None of these companies operate under anything resembling the EU's high-risk conformity regime for their core products, though EU-facing obligations do apply to their general-purpose models under the GPAI provisions that took effect in August 2025. The absence of a binding high-risk product classification for a general-purpose chatbot, as opposed to a purpose-built hiring or credit-scoring tool, is itself a structural advantage: US labs can ship a single global model and treat region-specific compliance as a secondary engineering problem, rather than a gating requirement before a product category can be sold at all.

Moonshot AI, Zhipu AI, and MiniMax (China) — State-Aligned Speed

China's "AI Tigers" show a third pattern entirely. Moonshot AI went from a4.3 billion valuation at the end of 2025 to 20 billion by May 2026, a nearly fivefold increase in about six months, backed by Meituan's venture arm, Tsinghua-linked capital, and China Mobile. Zhipu AI (trading as Knowledge Atlas Technology) and MiniMax both completed Hong Kong IPOs in the same window, reaching market caps of roughly55.9 billion and 33 billion respectively. This is not primarily foreign venture capital chasing yield; it's a mix of domestic platform companies, state-linked funds, and a national "AI+" policy adopted in July 2025 that explicitly promotes open-weight model development with accompanying subsidies for adoption. Compliance in this system is less about conformity assessments and more about alignment with government priorities from day one, which removes a large category of uncertainty that EU and even US founders have to manage on their own, at the cost of ceding strategic direction to the state.

Two Competing Read-Outs on What the EU Act Means for High-Risk Founders

Where investors and founders diverge is in what all this data means for high-risk classified startups specifically, and there are genuinely two credible camps.

One camp, echoed in an open letter signed by more than thirty founders and investors including Johannes Schildt, Anton Osika, and Fredrik Hjelm, argues the Act's fragmented and unpredictable rollout discourages investment outright and pushes both capital and talent toward more permissive markets. Surveys from ACT | The App Association back this up at the operational level: roughly six in ten EU and UK startups report delayed access to frontier models, and more than a third say they have had to strip features to stay compliant. The same research estimates annual revenue at risk of31,000 to $62,000 per affected small tech firm, rising to over $200,000 for the most directly affected, plus tens of thousands more in foregone savings for users waiting on delayed features. Nearly 70 percent of founders in Atomico's survey separately called the regulatory environment too restrictive, a remarkably consistent number across two independently run studies.

The opposing view, gaining traction among later-stage investors, is that regulatory certainty is becoming a moat rather than a tax. Companies that have built compliance into their product from the start, since the Act's outline was known as early as 2021, are increasingly winning procurement in regulated sectors like banking, insurance, and public health, where buyers now treat AI Act alignment as a baseline requirement rather than a nice-to-have. Some later-stage European AI rounds are reportedly seeing rising participation from US and Asian investors specifically because compliance-by-design reduces downstream regulatory risk in a global sales motion, and almost half of funding for European late-stage startups overall is already coming from US and Asian investors, according to Atomico, a sign that foreign capital is not avoiding Europe so much as cherry-picking within it.

The Specific Categories Where the Divide Is Sharpest

Not every high-risk category is affected equally, and this is where founders building in a specific vertical should pay close attention.

Healthcare AI faces some of the heaviest compounding costs, since diagnostic and triage tools often sit under both the AI Act's high-risk rules and existing medical device regulation, pushing validation costs up an estimated 20 to 40 percent above baseline compliance figures. This is precisely the category where European researchers warn that certification burdens could concentrate innovation among larger, better-capitalized incumbents and squeeze out smaller challengers, even though the same rules are meant to protect patients.

HR and hiring tools are arguably the most exposed category to date, since CV-screening and candidate-ranking systems are explicitly named in Annex III, and any company in this space has to assume high-risk classification as the default rather than the exception. Vestbee's reporting captured this directly: an EU business using AI to screen, rank, or match candidates is now regulated as high-risk, full stop, with obligations covering the entire operating model, not just the algorithm.

Biometrics and identity verification sit at the sharpest edge of the Act, since real-time public biometric identification is banned outright and other biometric categorization use cases are treated as high-risk by default. This is also the category where the contrast with China is most stark: Chinese biometric and surveillance AI firms have historically had an easier regulatory and funding path domestically, precisely because state alignment substitutes for the kind of fundamental-rights review the EU insists on.

Credit scoring and insurance underwriting AI, similarly, faces high-risk treatment plus overlapping GDPR obligations, meaning European fintech-AI startups in this space often need double compliance infrastructure, one for the AI Act and one for existing financial-services data law, doubling much of the legal overhead relative to a comparable US fintech building the same feature.

What This Means for Founders Building in Regulated Categories

For a founder building anything that touches hiring, credit, biometrics, healthcare diagnostics, or critical infrastructure, several things follow from all of the above.

First, the compliance timeline has become a live variable in fundraising conversations, not a footnote, since the AI Omnibus delay shows the goalposts can and do move mid-cycle, sometimes by more than a year. Second, capital concentration is real and getting more extreme: a small number of frontier labs and late-stage rounds are absorbing a disproportionate share of global AI funding, which means high-risk classified startups, wherever they are based, are competing for a shrinking slice of investor attention outside of the largest players. Third, geography is becoming a strategic choice rather than a default. Founders are increasingly weighing where to incorporate and where to serve customers first based on which regulatory regime their category falls under, and that calculation now shows up explicitly in cap tables and headquarters decisions, not just in press-release rhetoric about "innovation-friendly" jurisdictions. Fourth, category matters more than geography alone: a European founder building a general-purpose coding assistant faces a very different regulatory reality than one building a hiring tool, even though both are nominally "AI startups" operating from the same city.

Conclusion: A Changed Shape, Not a Stopped Flow

The honest summary is that the EU AI Act has not stopped venture capital from reaching high-risk classified startups in Europe, but it has changed its shape: slower to close, more concentrated in compliance-ready teams, increasingly co-financed by investors outside the bloc who are betting that regulatory rigor becomes a selling point once the rest of the world catches up, and structurally smaller in scale than either the US frontier-lab boom or China's state-turbocharged funding surge. Mistral's trajectory shows Europe can still produce genuine scale-ups even under the heaviest compliance regime in the world. The open letters and survey data show that a meaningful share of the founder base still experiences that regime as a drag rather than a moat. Both things are true at once, and which one dominates for any individual startup depends heavily on which Annex III category it falls into, how well-capitalized it is going into the compliance cliff, and whether its buyers are the kind of regulated institutions that reward AI Act alignment as a procurement signal. Whether the "moat" thesis wins out before Europe's late-stage funding gap widens further is the open question for the next two enforcement cycles, and it is likely to be answered category by category rather than all at once.